Novo Nordisk's diabetes drug liraglutide beat a commonly used rival, Sanofi-Aventis' glimepiride, in controlling blood sugar and caused some patients to lose weight, according to a two-year trial. The study showed a 1.1% decline in A1C blood-sugar levels in patients taking liraglutide compared with a 0.6% reduction in those taking glimepiride.

Full Story:

Related Summaries